Mucopolysaccharidosis (MPS) Treatment Market, By Treatment, By MPS Type, By End User, By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Description

Mucopolysaccharidosis (MPS) Treatment Market is estimated to be valued at USD 2.75 Bn in 2025 and is expected to reach USD 5.39 Bn by 2032, growing at a compound annual growth rate (CAGR) of 10.1% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 2.75 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	10.10%	2032 Value Projection:	USD 5.39 Bn

The treatment of Mucopolysaccharidosis (MPS) is primarily focused on managing symptoms, improving the quality of life, and slowing down the progression of the disease. MPS is a group of rare genetic disorders characterized by the accumulation of glycosaminoglycans (GAGs) in cells and tissues due to deficiencies in specific enzymes responsible for breaking down these complex sugars. Enzyme Replacement Therapy (ERT): This is the mainstay treatment for many types of MPS. In ERT, the missing or deficient enzyme is administered intravenously to help break down the accumulated GAGs. Although ERT can be beneficial, it may not effectively treat neurological symptoms because the enzyme may not efficiently cross the blood-brain barrier. Hematopoietic Stem Cell Transplantation (HSCT): Also known as bone marrow transplantation, HSCT involves transplanting healthy stem cells from a donor into the patient's bone marrow. The donor cells can produce the missing enzyme, leading to a potential reduction in GAG accumulation. HSCT is most effective when performed early in the disease course before significant irreversible damage has occurred.

Market Dynamics

Market players are focusing on various inorganic growth strategies such as collaborations for the treatment mucopolysaccharidosis (MPS), which is expected to boost the global mucopolysaccharidosis (MPS) treatment market growth. For instance, In September 2021, Takeda Pharmaceuticals, a patient-focused, R&D-driven, global biopharmaceutical company committed to bringing Better Health and a Brighter Future, entered into an exclusive collaboration and license agreement with JCR Pharmaceuticals is a global specialty pharmaceuticals company, to commercialize JR-141, an investigational next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme for the treatment of Hunter syndrome. Under the terms of the agreement, Takeda commercialized JR-141 outside of the U.S., including Canada, Europe, and other regions (excluding Japan and certain other Asia Pacific countries). JCR received an upfront payment for such an ex-US license and is eligible to receive additional development and commercial milestones, as well as tiered royalties on potential sales.

Key features of the study:

This report provides an in-depth analysis of the global mucopolysaccharidosis (MPS) treatment market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global mucopolysaccharidosis (MPS) treatment market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
Global mucopolysaccharidosis (MPS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global mucopolysaccharidosis (MPS) treatment market.

Detailed Segmentation:

Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment:
- Enzyme Replacement Therapy
- Stem Cell Therapy
Global Mucopolysaccharidosis (MPS) Treatment Market, By MPS Type:
- MPS-I
- MPS-II
- MPS-IV
- MPS-VI
- MPS-VII
- Others (MPS-III and MPS-IX)
Global Mucopolysaccharidosis (MPS) Treatment Market, By End User:
- Hospitals
- Specialty Clinics
- Others
Global Mucopolysaccharidosis (MPS) Treatment Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- Takeda Pharmaceutical Company Limited
- BioMarin Pharmaceuticals, Inc.
- Ultragenyx Pharmaceutical Inc.
- Sarepta Therapeutics
- Abeona Therapeutics Inc.
- Eloxx Pharmaceuticals
- Esteve
- Immusoft Corporation
- Inventiva
- GC Pharma
- JCR Pharmaceuticals Co Ltd.
- RegenxBio Inc.
- Sangamo Therapeutics, Inc.
- Bioasis Technologies Inc.
- Paradigm Biopharmaceuticals Ltd.

Product Code: CMI4184

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Treatment
- Market Snippet, By MPS Type
- Market Snippet, By End User
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Drug Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Mucopolysaccharidosis (MPS) Treatment Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment, 2020-2032 (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Enzyme Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Segment Trends
Stem Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Segment Trends

6. Global Mucopolysaccharidosis (MPS) Treatment Market, By MPS Type, 2020-2032 (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
MPS-I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
MPS-II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
MPS-IV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
MPS-VI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
MPS-VII
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Others (MPS-III and MPS-IX)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

7. Global Mucopolysaccharidosis (MPS) Treatment Market, By End User, 2020-2032 (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

8. Global Mucopolysaccharidosis (MPS) Treatment Market, By Region, 2020-2032 (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2020-2032, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2020-2032, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2020-2032, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2020-2032, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2020-2032, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2020-2032, (US$ Bn)
- Market Size and Forecast, By Country/Region, and Y-o-Y Growth 2020-2032, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Takeda Pharmaceutical Company Limited
  - Company Overview
  - Device Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- BioMarin Pharmaceuticals, Inc.
  - Company Overview
  - Device Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Ultragenyx Pharmaceutical Inc.
  - Company Overview
  - Device Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Sarepta Therapeutics
  - Company Overview
  - Device Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Abeona Therapeutics Inc.
  - Company Overview
  - Device Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Eloxx Pharmaceuticals
  - Company Overview
  - Device Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Esteve
  - Company Overview
  - Device Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Immusoft Corporation
  - Company Overview
  - Device Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Inventiva
  - Company Overview
  - Device Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- GC Pharma
  - Company Overview
  - Device Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- JCR Pharmaceuticals Co Ltd.
  - Company Overview
  - Device Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- RegenxBio Inc.
  - Company Overview
  - Device Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Sangamo Therapeutics, Inc.
  - Company Overview
  - Device Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Bioasis Technologies Inc.
  - Company Overview
  - Device Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Paradigm Biopharmaceuticals Ltd.
  - Company Overview
  - Device Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies

10. Section

References
Research Methodology
About us and Sales Contact